MEDP · Medpace Holdings Inc
Price
Snapshot
50 fields · last close| Market Cap | $16.50B |
| P/E | 33.58 |
| Float | 22.38M |
| Beta | 1.13 |
| Volatility | 28.3% |
| Exchange | NASDAQ |
| Sector | Life Sciences Tools & Services |
| Cap tier | Large cap |
| Macro sensitivity | Moderate |
| Clavix score | 70 |
| Price | 591.29 |
| Change | −0.01% |
| Prev Close | 591.33 |
| Open | 585.10 |
| Day Low | 585.00 |
| Day High | 596.00 |
| Avg Vol | 0 |
| Avg $ Vol | $117.6M |
| 52W High | 677.90 |
| 52W Low | 373.00 |
| 52W Pos | 71.6% |
| From High | −12.78% |
| From Low | +58.52% |
| Max DD 1Y | −36.61% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | −1.57% |
| SMA 50 | +3.00% |
| SMA 200 | +13.54% |
| RSI (14) | 50.6 |
| Vol 30D | 25.9% |
| Vol 90D | 35.9% |
| 1Y Range | 373–678 |
| Daily bars | 507 |
| Perf Week | −1.56% |
| Perf Month | +1.07% |
| Perf Quarter | +30.17% |
| Perf Half Y | +25.65% |
| Perf Year | +22.59% |
| Perf YTD | +3.55% |
| Prev Day | −0.01% |
| Clavix | B- |
| Debt / Eq | 0.00 |
| Curr Ratio | 0.74 |
| Int Cover | 100.5× |
| FCF Margin | 25.9% |
| Rev Growth | +17.2% |
| Profit | Profitable |
| Leverage | Low |
| Sector rank | 9 / 19 |
Clavix risk grade
regraded every trading dayMEDP grades B-, 70 of 100. Steadiest on News Sentiment (69), most exposed on Price Stability (59, mixed). 2 of the 4 weighted dimensions sit above the Life Sciences Tools & Services median. Ranks 9 of 19 in Life Sciences Tools & Services by Clavix score.
How rough the ride is
| MEDP | Life Sciences Tools & Services median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 1.13 | 1.19 |
| Volatilityannualized | 28.3% | 29.7% |
| Max drawdown, past yearworst peak-to-trough fall | −36.6% | — |
| Typical daily movemedian absolute daily change | 1.16% | — |
| Days beyond ±3%of the last 252 sessions | 3313% | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| MEDP | Life Sciences Tools & Services median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 1.13 | 1.19 |
| Macro sensitivityrate, dollar and credit exposure bucket | Moderate | Moderate47% of 19 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Life Sciences Tools & Services names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| MEDP | |
|---|---|
| 1 week | −1.6% |
| 1 month | +1.1% |
| Year to date | +3.5% |
| 1 year | +22.6% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| MEDP | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30since 22 Jul |
| Average score0 most bearish, 100 most bullish | 66 |
| Bullish · bearisharticles above 60 · below 40 | 23 · 5 |
| Directionarticles whose tone is improving vs worsening | 23 ↑ 5 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 19 Life Sciences Tools & Services names Clavix covers; the tick is the sector median.
Growth
| MEDP | |
|---|---|
| Revenue growthyear over year | +17.2% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Life Sciences Tools & Services median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Against Life Sciences Tools & Services
19 companies| Metric | MEDP | Sector spread | Median |
|---|---|---|---|
| Beta | 1.13 | 1.19 | |
| Volatility | 28.3% | 29.7% | |
| P/E | 33.58 | 36.46 | |
| Debt / equity | 0.00 | 0.51 | |
| Current ratio | 0.74 | 1.89 | |
| FCF margin | 25.9% | 18.8% | |
| Interest coverage | 100.5× | 3.5× |
Recent news
most recent scored articles · the chip is the article’s score · click to openCaisse de depot et placement du Quebec, a large Canadian institutional investor, disclosed a brand-new position in Medpace Holdings during the second quarter, buying 152,908 shares for roughly $81 million.
Medpace CEO August Troendle sold 13,995 shares of company stock on Friday, August 21st at an average price of $624.45, for a total of about $8.74 million. After the sale, he still directly owns 547,200 shares.
Medpace stock has fallen back below a buy point of $628.92, even though the medical research contractor reported better-than-expected earnings for the second quarter. The piece frames the pullback as a 'second chance' for buyers after a July spike.
Medpace's stock dropped back below a buy point of $628.92 after a July spike. The medical research contractor reported second-quarter earnings that beat expectations.
Medpace CEO Troendle sold 15,978 shares at a weighted-average price of $623.93 over two trading days ending August 24, 2026, totaling about $10 million. The shares sold represent 3% of his directly held stake and 0.3% of his total combined holding in the company.
Nearest peers by size
Life Sciences Tools & Services| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| RVTY | Revvity Inc | B | $14.53B | 61.17 | 1.11 | Compare |
| CRL | Charles River Laboratories International Inc | B- | $13.77B | — | 1.41 | Compare |
| TEM | Tempus AI Inc | D- | $11.66B | — | 2.34 | Compare |
| WST | West Pharmaceutical Services Inc | B+ | $23.90B | 42.35 | 1.16 | Compare |
| TECH | Bio-Techne Corp | B- | $11.36B | 62.46 | 1.30 | Compare |
| AVTR | Avantor Inc | B- | $10.13B | — | 0.98 | Compare |
| MTD | Mettler-toledo International Inc | B+ | $26.95B | 29.76 | 1.21 | Compare |
| RGEN | Repligen Corp | B- | $9.46B | 227.70 | 1.14 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. Three months free on iPhone.